Accera Reports Results Of 90-Day Clinical Study For Axona

Accera has announced that data showed that using ketone bodies can be an effective and safe method to approach Alzheimer’s Disease. The results were published as scientific paper in the journal Nutrition & Metabolism.

The paper, entitled-Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial, suggests that daily administration of AC-1202 (Axona) can help improve cognition and memory in patients with mild-to-moderate Alzheimer’s disease (AD).

The study was conducted in 152 patients at 23 clinical sites throughout the US. The study examined the effects of AC-1202 on performance in the Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-Cog). Notably, participants in the study were allowed to remain on their current Alzheimer’s disease medications and did not have to alter their diets in any way.

AC-1202 was found to be safe and produced a beneficial trend for the overall subject population and significant cognitive benefits in a predefined analysis of patients who did not carry the epsilon 4 (E4) variant of the apolipoprotein E gene (APOE4).

In addition, there was a significant correlation between improvement in cognition and memory and amount of AC-1202 consumed by APOE4(-) patients.

Samuel Henderson, executive director of research at Accera and lead author of the paper, said: Accera has taken a novel approach to Alzheimer’s therapy with the development of Axona. Publication of our findings confirms our earlier pre-clinical and clinical findings which show that using ketone bodies can be an effective and safe method to approach this devastating disease.